Omission of Intact Parathyroid Hormone Testing During Surgery in Treating Patients With Primary Hyperparathyroidism

Primary Hyperparathyroidism Clinical Trial

Official title:

Single-Arm, Non-inferiority Study of Omission of Intraoperative Intact Parathyroid Hormone (PTH) During Minimally Invasive Parathyroidectomy for Primary Hyperparathyroidism

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03011736
• Other study ID #: I 274915
• Secondary ID: NCI-2016-01974I
• Status: Completed
• Phase: N/A
• Start date: May 12, 2016
• Est. completion date: December 24, 2018

Study information

• Verified date: August 2021
• Source: Roswell Park Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial studies the omission of intact parathyroid hormone testing during surgery in treating patients with primary hyperparathyroidism. Omission of intact parathyroid hormone testing during parathyroid gland removal may help patients with primary hyperparathyroidism to decrease their time under anesthesia, and decrease the overall time and cost of surgery.

Description:

PRIMARY OBJECTIVES:

I. Determine the non-inferiority of omission of parathyroid hormone (PTH) in patients who meet the biochemical and radiological criteria compared to current standard of care (i.e. use of intraoperative parathyroid hormone testing).

SECONDARY OBJECTIVES:

I. Cost-analysis to determine savings of omission of intraoperative PTH testing.

OUTLINE:

Patients undergo standard minimally invasive parathyroidectomy without PTH testing during surgery.

After completion of study, patients are followed up at 2 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: December 24, 2018
• Est. primary completion date: July 12, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Positive 4 dimensional computed tomography (4D CT) for single gland (adenoma) primary hyperparathyroidism

• Preoperative serum calcium levels >= 10.9 mg/dL

• Preoperative parathyroid hormone (PTH) elevated beyond normal range or inappropriately high for associated calcium level

• Patient has no history of prior neck surgery or external radiation to neck for malignant conditions

• Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2

• Subject or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion Criteria:

• Patient has recurrent hyperparathyroidism

• 4D CT positive for multiple gland disease

• Patient has inability to tolerate 4D CT scan (for example; contrast intravenous (IV) allergy, claustrophobia, renal disease)

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

• Pregnant or nursing female subjects; may be determined in the preoperative evaluation

• Unwilling or unable to follow protocol requirements

• Any condition which in the investigator's opinion deems the subject an unsuitable candidate to undergo observational study (may also include preoperative testing results including electrocardiography [EKG], chest x-ray, or pulmonary function tests that preclude a wide excision in the operating room)

Related Conditions & MeSH terms

• Adenoma
• Hyperparathyroidism
• Hyperparathyroidism, Primary
• Parathyroid Gland Adenoma
• Primary Hyperparathyroidism

Intervention

Other:
• Laboratory Biomarker Analysis
Correlative studies

Procedure:
• Parathyroidectomy
Undergo parathyroidectomy

Locations

Country	Name	City	State
United States	Roswell Park Cancer Institute	Buffalo	New York

Sponsors (1)

Lead Sponsor	Collaborator
Roswell Park Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cure of primary hyperparathyroidism following surgery with intraoperative PTH omission	Will be evaluated using a binomial exact test. If all N=60 patients achieve cure then the proposed surgery with intraoperative PTH testing committed will be considered non inferior. A 95% confidence interval about pi will be obtained.	At 2 weeks
Secondary	Post-operative cost analysis	cost analysis will be based on operative time and omission of intraoperative PTH levels.	At 2 weeks